Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Pemetrexed + Carboplatin in Advanced Nonsquamous NSCLC
NCT03790228Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 42 days. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03790228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790228.